Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

4
18
1

Year Published

2021
2021
2023
2023

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 17 publications
(23 citation statements)
references
References 29 publications
4
18
1
Order By: Relevance
“…Although previous meta-analyses (28)(29)(30)(31)(32)(33)(34) have compared the efficacy and safety of roxadustat vs. placebo or ESA, the results showed that roxadustat was more effective than placebo and noninferior to ESA in correcting anemia in CKD patients. However, evidence for the results is still lacking and several new clinical trials have been conducted to compare roxadustat with placebo or ESA for the treatment of anemia in NDD-CKD or DD-CKD patients.…”
Section: Discussionmentioning
confidence: 96%
“…Although previous meta-analyses (28)(29)(30)(31)(32)(33)(34) have compared the efficacy and safety of roxadustat vs. placebo or ESA, the results showed that roxadustat was more effective than placebo and noninferior to ESA in correcting anemia in CKD patients. However, evidence for the results is still lacking and several new clinical trials have been conducted to compare roxadustat with placebo or ESA for the treatment of anemia in NDD-CKD or DD-CKD patients.…”
Section: Discussionmentioning
confidence: 96%
“…All published phase II trials indicate that HIF-PHI therapy is at least as efficacious as conventional ESA therapy in managing Hb levels in both nondialysis-dependent CKD (ND-CKD and dialysis-dependent (DD-CKD) patients [ 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 ]. The meta-analysis of 26 randomized controlled trials involving 2804 patients with CKD comparing the use of HIF-PHIs versus ESAs or placebo in the treatment of renal anemia found HIF-PHIs superior to placebo and at least as efficacious as classic ESAs in the short term [ 5 ].…”
Section: Hypoxia-inducible Factor Inhibitorsmentioning
confidence: 99%
“…The meta-analysis of 26 randomized controlled trials involving 2804 patients with CKD comparing the use of HIF-PHIs versus ESAs or placebo in the treatment of renal anemia found HIF-PHIs superior to placebo and at least as efficacious as classic ESAs in the short term [ 5 ]. Likewise, a meta-analysis by Qie et al, including 1010 patients, showed that roxadustat has a higher mean Hb level than placebo or EPO [ 91 ]. HIF-PHIs have demonstrated efficacy and safety in phase 2 and 3 trials in several different cohorts of CKD patients with anemia who are either ND-CKD or DD.…”
Section: Hypoxia-inducible Factor Inhibitorsmentioning
confidence: 99%
See 1 more Smart Citation
“…46 A 2021 meta-analysis of 8 phase 2 and 3 studies of roxadustat demonstrated significant increases vs. control (placebo and ESAs) in TIBC (P<0.00001) and serum iron level (p=0.05); significant reductions in hepcidin (P<0.0001) and ferritin (P<0.00001). 47 The global phase 3 program for roxadustat includes 4 studies in NDD-CKD patients (ALPS, ANDES, and OLYMPUS using placebo control; DOLOMITES using ESA control) and 4 studies in DD-CKD patients (HIMALAYAS, ROCKIES and SIERRAS using epoetin control; PYRENEES using epoetin or darbepoetin control). The first two publications 48,49 from the roxadustat global phase 3 program appeared in Kidney International Reports in 2021, accompanied by an editorial.…”
Section: Roxadustatmentioning
confidence: 99%